LUIS GONZAGA
PAZ-ARES RODRÍGUEZ

2026

1. A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)

   ESMO Open, Vol. 11, Núm. 1

2. AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti–PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or More

   Journal of Thoracic Oncology

3. Antibody-Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond

   Journal of Thoracic Oncology, Vol. 21, Núm. 9

4. Antibody–drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

   ESMO Open, Vol. 11, Núm. 8

5. Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial (Nature Medicine, (2026), 10.1038/s41591-026-04452-0)

   Nature Medicine

6. Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial)

   Journal of translational medicine, Vol. 24, Núm. 1

7. Brief report: Artificial intelligence meets small cell lung cancer—integrating clinicopathological and wholeslide image data for prognostic prediction in SCLC

   Frontiers in Artificial Intelligence, Vol. 9

8. Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC

   Journal of Thoracic Oncology, Vol. 21, Núm. 7

9. Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial

   Journal of Thoracic Oncology, Vol. 21, Núm. 7

10. Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial

    Journal of Thoracic Oncology, Vol. 21, Núm. 8

11. Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 32, Núm. 16, pp. 3517-3530

12. Emerging Targeted Therapies for HER2-Mutant NSCLC

    Journal of Thoracic Oncology

13. Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer

    Journal of Clinical Oncology, Vol. 44, Núm. 13, pp. 1190-1197

14. High Endothelial Venules as Conduits for Antitumor Immune Cell Trafficking in Small Cell Lung Cancer

    International Journal of Cancer

15. Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 44, Núm. 4, pp. 261-273

16. Influence of CT harmonization in longitudinal radiomics for NSCLC immunotherapy response prediction

    Computers in Biology and Medicine, Vol. 203

17. NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum

    EMBO Molecular Medicine, Vol. 18, Núm. 2, pp. 514-541

18. Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study

    Lung Cancer, Vol. 211

19. Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial

    JTO Clinical and Research Reports, Vol. 7, Núm. 2

20. Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

    Lung Cancer, Vol. 213